US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

11.01

-0.1100-0.99%

Post-market: 11.010.00000.00%16:15 EDT

Volume:390.33K

Turnover:4.29M

Market Cap:3.73B

PE:115.43

High:11.10

Open:11.08

Low:10.93

Close:11.12

52wk High:13.11

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:1.09

T/O Rate:0.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0954

EPS(LYR):-0.0211

ROE:7.36%

ROA:2.71%

PB:7.65

PE(LYR):-521.80

Loading ...

Overview Company News Filings

Telix Pharmaceuticals (ASX:TLX) Shares Valuation After New Theranostics Collaboration With United Imaging

Simply Wall St.

Early ProstACT Phase 3 Safety Data Could Be A Game Changer For Telix (ASX:TLX)

Simply Wall St.

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After United Imaging Deal And Phase 3 TLX591-Tx Update

Simply Wall St.

What Telix Pharmaceuticals (ASX:TLX)'s ProstACT Safety Data and Theranostic Partnership Expansion Means For Shareholders

Simply Wall St.

Telix and United Imaging Announce Strategic Theranostics Collaboration

Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial

MT Newswires Live

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026

Telix Issues New Tranche of Unquoted Equity Under Employee Incentive Schemes

Telix boosts CEO equity incentives with new long-term rights grant

Telix Grants Share Appreciation Rights to Director Marie McDonald

Telix Grants Share Appreciation Rights to Director David Gill

How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Glioblastoma Trial Enrolment Milestone

Simply Wall St.

Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences

A Look At Telix Pharmaceuticals’ Valuation As TLX101-Tx Glioblastoma Study Hits Key Safety Milestone

Simply Wall St.

Analyst Reiterates Buy on Telix Pharmaceuticals, Sees 38–42% Upside with Unchanged $22.4 Price Target

Canaccord Genuity Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Telix underscores radiopharma portfolio and regulatory risks at shareholder meeting

Telix boosts radiopharma scale and pivots deeper into cancer therapeutics

Telix Pharmaceuticals Completes Enrollment in Brain Cancer Drug Trial

MT Newswires Live

IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/TLX/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":11.01,"timestamp":1791489600000,"preClose":11.12,"halted":0,"volume":390334,"hourTrading":{"tag":"盘后","latestPrice":11.01,"preClose":11.01,"latestTime":"16:15 EDT","volume":111,"amount":1222.11,"timestamp":1791490500237,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0098920863309352,"floatShares":272000000,"shares":339000000,"eps":0.095386,"marketStatus":"Post-Mkt","change":-0.11,"latestTime":"10-08 17:01:30 EDT","open":11.08,"high":11.1,"low":10.93,"amount":4292525,"amplitude":0.015288,"askPrice":11.25,"askSize":5,"bidPrice":10.4,"bidSize":5,"shortable":3,"etf":0,"ttmEps":0.095386,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791504000000},"marketStatusCode":4,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":11.12,"preHourTrading":{"tag":"盘前","latestPrice":11,"preClose":11.12,"latestTime":"07:11 EDT","volume":174,"amount":1888.419912,"timestamp":1791457917068,"change":-0.12,"changeRate":-0.010791,"amplitude":0.036871},"postHourTrading":{"tag":"盘后","latestPrice":11.01,"preClose":11.01,"latestTime":"16:15 EDT","volume":111,"amount":1222.11,"timestamp":1791490500237,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.090779},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.71%","roe":"7.36%","lyrEps":-0.0211,"volumeRatio":1.090779,"shares":339000000,"dividePrice":0,"high":11.1,"amplitude":0.015288,"preClose":11.12,"low":10.93,"week52Low":6.28,"pbRate":"7.65","psRate":"4.19","week52High":13.1098,"institutionHeld":0,"latestPrice":11.01,"eps":0.095386,"divideRate":0,"volume":390334,"delay":0,"ttmEps":0.095386,"open":11.08,"prevYearClose":7.49,"prevWeekClose":10.55,"prevMonthClose":10.97,"prevQuarterClose":10.97,"fiveDayClose":10.72,"twentyDayClose":11.9,"sixtyDayClose":11.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758254400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-10-07","current":116.578953,"percent":0.27907,"low":-584.49693,"twenty":-429.411057,"median":169.604202,"eighty":241.190668,"high":383.853933,"avg":28.330875,"sd":304.807262,"marketCap":3753307402.38},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03},{"date":"2026-04-02","current":-425.435204,"twenty":162.890567,"median":182.629922,"eighty":285.17117,"marketCap":3031225831.43},{"date":"2026-04-10","current":-492.382264,"twenty":161.467054,"median":181.810223,"eighty":284.24913,"marketCap":3508223631.57},{"date":"2026-04-17","current":-499.465833,"twenty":158.955031,"median":181.091444,"eighty":284.07528,"marketCap":3558694058.36},{"date":"2026-04-24","current":-507.89561,"twenty":156.233199,"median":180.584513,"eighty":282.031139,"marketCap":3618756217.23},{"date":"2026-05-01","current":-532.518745,"twenty":154.872282,"median":180.00406,"eighty":281.147736,"marketCap":3794196059.21},{"date":"2026-05-08","current":-508.824558,"twenty":144.045965,"median":179.412236,"eighty":280.966174,"marketCap":3625374971.37},{"date":"2026-05-15","current":-506.065728,"twenty":140.182144,"median":178.86094,"eighty":280.209239,"marketCap":3605718311.9},{"date":"2026-05-22","current":-452.537308,"twenty":125.947014,"median":178.262158,"eighty":280.194275,"marketCap":3224328322.29},{"date":"2026-05-29","current":-444.681415,"twenty":120.122064,"median":178.059203,"eighty":279.725537,"marketCap":3168355079.47},{"date":"2026-06-05","current":-452.683664,"twenty":115.968865,"median":177.318176,"eighty":279.589795,"marketCap":3225371110.32},{"date":"2026-06-12","current":-453.131496,"twenty":29.784924,"median":176.508379,"eighty":278.469383,"marketCap":3228561906.13},{"date":"2026-06-18","current":-479.232706,"twenty":-319.885885,"median":176.029393,"eighty":275.361846,"marketCap":3414533028.17},{"date":"2026-06-26","current":-505.22407,"twenty":-336.088027,"median":175.625224,"eighty":265.637187,"marketCap":3599721496.58},{"date":"2026-07-02","current":-567.292731,"twenty":-347.690038,"median":175.082406,"eighty":259.576863,"marketCap":4041960704.33},{"date":"2026-07-10","current":-538.02731,"twenty":-371.335373,"median":174.480785,"eighty":256.751103,"marketCap":3833444584.84},{"date":"2026-07-17","current":-497.824928,"twenty":-406.861587,"median":173.909122,"eighty":252.484997,"marketCap":3547002606.6},{"date":"2026-07-24","current":-487.362208,"twenty":-419.925535,"median":173.731386,"eighty":249.449835,"marketCap":3472455733.71},{"date":"2026-07-31","current":-475.018244,"twenty":-425.317007,"median":173.324997,"eighty":249.116107,"marketCap":3384504988.78},{"date":"2026-08-07","current":-543.110083,"twenty":-431.380818,"median":173.121803,"eighty":248.587668,"marketCap":3869659340.88},{"date":"2026-08-14","current":-563.285348,"twenty":-444.416873,"median":172.850024,"eighty":247.242146,"marketCap":4013408103.64},{"date":"2026-08-21","current":112.812357,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"marketCap":3778875522.96},{"date":"2026-08-28","current":114.191675,"twenty":-444.681415,"median":171.69944,"eighty":244.665977,"marketCap":3825078550.57},{"date":"2026-09-04","current":120.218119,"twenty":-444.416873,"median":171.125205,"eighty":244.246526,"marketCap":4026946335.18},{"date":"2026-09-11","current":113.993217,"twenty":-443.358706,"median":170.839525,"eighty":243.230652,"marketCap":3818430784.57},{"date":"2026-09-18","current":128.771395,"twenty":-438.399131,"median":170.279278,"eighty":242.301839,"marketCap":4313455406.44},{"date":"2026-09-25","current":113.11909,"twenty":-435.525335,"median":170.22876,"eighty":242.197204,"marketCap":3789150143.08},{"date":"2026-10-02","current":106.450812,"twenty":-432.365699,"median":169.774316,"eighty":242.047247,"marketCap":3565782844.39},{"date":"2026-10-07","current":112.049061,"twenty":-429.411057,"median":169.604202,"eighty":241.190668,"marketCap":3753307402.38}],"updateTime":1791456422802},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643878008","title":"Telix Pharmaceuticals (ASX:TLX) Shares Valuation After New Theranostics Collaboration With United Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2643878008","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643878008?lang=en_us&edition=fundamental","pubTime":"2026-06-16 08:24","pubTimestamp":1781569466,"startTime":"0","endTime":"0","summary":"Why Telix’s new collaboration is back in focus for ASX:TLX holders\nTelix Pharmaceuticals (ASX:TLX) has drawn investor attention after signing a Memorandum of Understanding with United Imaging Healthcare North America to explore integrated theranostics workflows in the United States.\nThe collaboration centers on combining United Imaging Healthcare’s scanner platforms, software, connectivity and AI tools with Telix’s molecular imaging portfolio and clinical protocols, initially focusing on...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-shares-valuation-after-new-ther","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-shares-valuation-after-new-ther","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","UBCP","BK4211","TLX.AU","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643216838","title":"Early ProstACT Phase 3 Safety Data Could Be A Game Changer For Telix (ASX:TLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643216838","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643216838?lang=en_us&edition=fundamental","pubTime":"2026-06-13 07:26","pubTimestamp":1781306805,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently reported Part 1 data from its ProstACT Global Phase 3 trial in metastatic castration-resistant prostate cancer, showing TLX591-Tx had an acceptable safety and tolerability profile with no new safety signals when combined with standard-of-care therapies.\nThe findings underline a potentially differentiated safety profile versus existing PSMA-targeted radioligand therapies, with lower kidney and salivary gland exposure that may be clinically meaningful for...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/early-prostact-phase-3-safety-data-could-be-a-game-changer-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/early-prostact-phase-3-safety-data-could-be-a-game-changer-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX.AU","TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641178819","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After United Imaging Deal And Phase 3 TLX591-Tx Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2641178819","media":"Simply Wall St.","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641178819?lang=en_us&edition=fundamental","pubTime":"2026-06-07 06:21","pubTimestamp":1780784516,"startTime":"0","endTime":"0","summary":"What the new United Imaging collaboration could mean for Telix\nTelix Pharmaceuticals (ASX:TLX) has signed a Memorandum of Understanding with United Imaging Healthcare North America to assess a U.S. focused research collaboration around integrated theranostics, immediately putting workflow and technology integration in the spotlight for investors.\nThe plan is to combine United Imaging’s scanner platforms, software, connectivity and AI tools with Telix’s molecular imaging portfolio and existing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-unite","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-unite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["UBCP","BK4211","TLX.AU","TLX","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640546711","title":"What Telix Pharmaceuticals (ASX:TLX)'s ProstACT Safety Data and Theranostic Partnership Expansion Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2640546711","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640546711?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:34","pubTimestamp":1780565694,"startTime":"0","endTime":"0","summary":"In recent days, Telix Pharmaceuticals reported Part 1 data from its Phase 3 ProstACT Global trial, showing TLX591-Tx had an acceptable safety and tolerability profile in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer, and entered a Memorandum of Understanding in the U.S. with United Imaging Healthcare North America to explore integrated theranostics solutions beginning with TLX101-Px.\nTogether, these developments highlight Telix’s efforts to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/what-telix-pharmaceuticals-asxtlxs-prostact-safety-data-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/what-telix-pharmaceuticals-asxtlxs-prostact-safety-data-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX","TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640917539","title":"Telix and United Imaging Announce Strategic Theranostics Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2640917539","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640917539?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:00","pubTimestamp":1780398000,"startTime":"0","endTime":"0","summary":"Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.Initial focus on TLX101-Px (Pixclara1, Floretyrosi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3304988/0/en/Telix-and-United-Imaging-Announce-Strategic-Theranostics-Collaboration.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","BK4211","ASX","BK4526","TLX","UBCP","BK4139","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906993","title":"Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906993","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906993?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:38","pubTimestamp":1780360721,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said its lutetium radio antibody-drug conjugate candidate, TLX591-Tx, demonstrated acceptable tolerability across all standard-of-care combination groups in the ProstAC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","TLX.AU","BK7067","BK7095","TLX","BK4139","IND.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640673389","title":"ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640673389","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640673389?lang=en_us&edition=fundamental","pubTime":"2026-06-02 05:00","pubTimestamp":1780347600,"startTime":"0","endTime":"0","summary":"Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304754/0/en/ProstACT-Global-Phase-3-Part-1-Data-Presented-in-Late-Breaking-Oral-Session-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASX","TLX","BK4139","BK4526","IND","BK4543","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640933600","title":"Telix Issues New Tranche of Unquoted Equity Under Employee Incentive Schemes","url":"https://stock-news.laohu8.com/highlight/detail?id=2640933600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640933600?lang=en_us&edition=fundamental","pubTime":"2026-06-01 13:38","pubTimestamp":1780292293,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals has issued a new tranche of unquoted equity securities under its em...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-tranche-of-unquoted-equity-under-employee-incentive-schemes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-tranche-of-unquoted-equity-under-employee-incentive-schemes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4215","BK4139","BK4588","TLX","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640935933","title":"Telix boosts CEO equity incentives with new long-term rights grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2640935933","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640935933?lang=en_us&edition=fundamental","pubTime":"2026-06-01 13:37","pubTimestamp":1780292258,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals has disclosed changes to the holdings of Managing Director and CEO ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-boosts-ceo-equity-incentives-with-new-long-term-rights-grant?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-boosts-ceo-equity-incentives-with-new-long-term-rights-grant?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640933981","title":"Telix Grants Share Appreciation Rights to Director Marie McDonald","url":"https://stock-news.laohu8.com/highlight/detail?id=2640933981","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640933981?lang=en_us&edition=fundamental","pubTime":"2026-06-01 13:27","pubTimestamp":1780291676,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals has disclosed a change in director Marie McDonald’s interests...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-grants-share-appreciation-rights-to-director-marie-mcdonald?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-grants-share-appreciation-rights-to-director-marie-mcdonald?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640933954","title":"Telix Grants Share Appreciation Rights to Director David Gill","url":"https://stock-news.laohu8.com/highlight/detail?id=2640933954","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640933954?lang=en_us&edition=fundamental","pubTime":"2026-06-01 13:27","pubTimestamp":1780291633,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an update. Telix Pharmaceuticals has granted 30,048 Share Appreciation Rights to director David Gill...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-grants-share-appreciation-rights-to-director-david-gill?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-grants-share-appreciation-rights-to-director-david-gill?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638656560","title":"How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Glioblastoma Trial Enrolment Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2638656560","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638656560?lang=en_us&edition=fundamental","pubTime":"2026-05-28 07:09","pubTimestamp":1779923368,"startTime":"0","endTime":"0","summary":"Earlier in May 2026, Telix Pharmaceuticals reported that its Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma completed enrolment, with no dose-limiting toxicities observed so far at doses up to 10GBq alongside standard-of-care therapy.\nThis progress, together with ongoing Phase 3 evaluation of TLX101-Tx as the first radiopharmaceutical therapy to reach this stage in glioblastoma, highlights Telix’s attempt to build a differentiated neuro-oncology franchise using...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-are-reacting-to-telix-pharmaceuticals-asxtlx-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-are-reacting-to-telix-pharmaceuticals-asxtlx-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK4211","BK4139","ISBC","BK7067","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638504953","title":"Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638504953","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638504953?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, May  27, 2026  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and G","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301768/0/en/Telix-to-Participate-in-William-Blair-Growth-Stock-and-Jefferies-Global-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LU0128526141.USD","TLX","BK4588","BK4139","BK4526","XLV","LABU","LU0029874061.USD","BK4141","BK4581","HCSG","ASX","BK4543","BK4585","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515809","title":"A Look At Telix Pharmaceuticals’ Valuation As TLX101-Tx Glioblastoma Study Hits Key Safety Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515809","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638515809?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:30","pubTimestamp":1779787849,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has reached a key clinical milestone by completing enrolment in its Phase 1 IPAX-2 study of investigational radiopharmaceutical TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities reported at the highest doses tested.\nSee our latest analysis for Telix Pharmaceuticals.\nDespite the positive glioblastoma update and new prostate cancer imaging collaborations, Telix Pharmaceuticals' share price is down 11.21% over the past month but up 43.8%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-valuation-as-tlx101-tx-gliob","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-valuation-as-tlx101-tx-gliob","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","TLX","BK4139","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638566243","title":"Analyst Reiterates Buy on Telix Pharmaceuticals, Sees 38–42% Upside with Unchanged $22.4 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2638566243","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638566243?lang=en_us&edition=fundamental","pubTime":"2026-05-26 08:45","pubTimestamp":1779756349,"startTime":"0","endTime":"0","summary":"In a report released on May 24, David Bailey from Morgan Stanley maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$22.40. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-telix-pharmaceuticals-sees-38-42-upside-with-unchanged-22-4-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-telix-pharmaceuticals-sees-38-42-upside-with-unchanged-22-4-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638563652","title":"Canaccord Genuity Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638563652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638563652?lang=en_us&edition=fundamental","pubTime":"2026-05-26 07:40","pubTimestamp":1779752408,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$30.00. Storey covers the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637322243","title":"Telix underscores radiopharma portfolio and regulatory risks at shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637322243","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637322243?lang=en_us&edition=fundamental","pubTime":"2026-05-21 22:33","pubTimestamp":1779374025,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals used its latest shareholder meeting materials to hig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-underscores-radiopharma-portfolio-and-regulatory-risks-at-shareholder-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-underscores-radiopharma-portfolio-and-regulatory-risks-at-shareholder-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","TLX","ARKG","BK4544","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637332210","title":"Telix boosts radiopharma scale and pivots deeper into cancer therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2637332210","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637332210?lang=en_us&edition=fundamental","pubTime":"2026-05-21 22:33","pubTimestamp":1779374008,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix used its 2025 Annual General Meeting to highlight strong commercial moment...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-boosts-radiopharma-scale-and-pivots-deeper-into-cancer-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-boosts-radiopharma-scale-and-pivots-deeper-into-cancer-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636500265","title":"Telix Pharmaceuticals Completes Enrollment in Brain Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636500265","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636500265?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:52","pubTimestamp":1779144775,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  has completed patient enrolment in the IPAX-2 study evaluating TLX101-Tx in newly diagnosed glioblastoma, with the company reporting no dose-limiting toxicities observed to date, according to a Tuesday statement.The study is a dose-finding trial evaluating TLX101-Tx in combination with standard post-surgical radiotherapy and temozolomide, and it will proceed with follow-up to establish the maximum tolerated dose.Twelve patients were enrolled in three dose-escalation cohorts across four sites in Australia, Austria, and the Netherlands to assess safety, tolerability, and determine the maximum tolerated dose.TLX101-Tx is also being evaluated in the ongoing pivotal phase three IPAX BrIGHT trial for recurrent glioblastoma, which is currently enrolling patients across multiple countries.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK4139","TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636001489","title":"IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636001489","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636001489?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:00","pubTimestamp":1779138000,"startTime":"0","endTime":"0","summary":"IPAX-2 study of TLX101-Tx (I-iodofalan) has completed patient enrolment.Maximum dose reached with no dose-limiting toxicities observed.TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, wh","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3297047/0/en/IPAX-2-Study-of-TLX101-Tx-in-First-line-Glioblastoma-Completes-Enrolment-and-Confirms-Dosing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4585","IE00BFXG0V08.USD","ASX","BK4543","MTD","BK4548","LU2413666699.HKD","BK4121","IE00B5TLWC47.USD","LU1093756168.USD","LU1093756325.SGD","LU2413666426.HKD","LU0347712357.USD","BK4139","LU2211817866.USD","IE00BYQQ9H92.USD","BK4141","BK4533","TLX","BK4588","BK4567","LU1721428933.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":199,"code":"91000000","status":"200"}]}}